021-51111890
购物车（）
sales@molnova.cn
Lificiguat
CAS No. 170632-47-0
Lificiguat ( YC1; YC 1; YC-1; Lificiguat )
产品货号. M18115 CAS No. 170632-47-0
YC-1 is an nitric oxide (NO)-independent activator of soluble guanylyl cyclase(sGC) and an inhibitor of Hypoxia-inducible factor-1alpha (HIF-1alpha).
纯度: 98%
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ￥348 | 有现货 |
|
| 10MG | ￥494 | 有现货 |
|
| 25MG | ￥1029 | 有现货 |
|
| 50MG | ￥2041 | 有现货 |
|
| 100MG | ￥3499 | 有现货 |
|
| 200MG | ￥5176 | 有现货 |
|
| 500MG | ￥7995 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称Lificiguat
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述YC-1 is an nitric oxide (NO)-independent activator of soluble guanylyl cyclase(sGC) and an inhibitor of Hypoxia-inducible factor-1alpha (HIF-1alpha).
-
产品描述Lificiguat, also known as YC-1, is a inhibitor of Hypoxia-inducible factor-1alpha (HIF-1alpha). YC-1 is widely used as a potent inhibitor of HIF-1alpha both in vitro and in vivo, and is also being developed as a novel anticancer drug. YC-1 effectively inhibits tumor invasion and metastasis, and imply that YC-1 is worth while to further develop as a multipurpose anticancer drug.
-
同义词YC1; YC 1; YC-1; Lificiguat
-
通路Others
-
靶点Other Targets
-
受体sGC;HIF-1α
-
研究领域Cancer
-
适应症——
化学信息
-
CAS Number170632-47-0
-
分子量304.34
-
分子式C19H16N2O2
-
纯度98%
-
溶解度DMSO : ≥ 51 mg/mL; 167.58 mM
-
SMILESOCC1=CC=C(C2=NN(CC3=CC=CC=C3)C4=C2C=CC=C4)O1
-
化学全称5-[1-(phenylmethyl)-1H-indazol-3-yl]-2-furanmethanol
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1.Martin E,etal.YC-1 activation of human soluble guanylyl cyclase has both heme-dependent and heme-independent components.Proc Natl Acad Sci U S A. 2001 Nov 6;98(23):12938-42.
产品手册
关联产品
-
anemarsaponin B
Anemarsaponin B has anti-inflammatory effect in LPS-treated RAW 264.7macrophages, the effect is associated with the inhibition of NF-κB transcriptional activity, possibly via the p38 MAP kinase pathway.
-
Eschweilenol C
Eschweilenol C has antifungal, anti-inflammatory, antioxidant, antidiabetic activity.
-
PKUMDL-WQ-2101
PKUMDL-WQ-2101 is a selective allosteric inhibitor of phosphoglycerate dehydrogenase (PHGDH) with anti-tumor activity, it binds to site I.
